Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x100px
Document › Details

Theolytics Ltd.. (1/7/21). "Press Release: Theolytics Raises $6.8 Million Series A Round Co-led by Epidarex Capital and Taiho Ventures to Advance Viral Cancer Therapies". Oxford.

Organisations Organisation Theolytics Ltd.
  Organisation 2 Epidarex Capital Partners LLC
  Group Epidarex Capital (Group)
Products Product oncolytic virus (cancer-cilling virus, virotherapy for cancer, virus-based cancer therapy)
  Product 2 venture capital
Index terms Index term Theolytics–SEVERAL: investment, 202101 financing round Series A £5m co-led by Epidarex Capital + Taiho Ventures
  Index term 2 Theolytics–Otsuka: investment, 202101 financing round Series A totalling £5m incl new + co-lead investor Taiho Ventures LLC
Persons Person Casebourne, Charlotte (Theolytics 202107 CEO + Co-Founder)
  Person 2 Steinhagen, Henning (Epidarex Capital 201909 CEO + Co-Founder of Epidarex Exeed before Aptuit + Grünenthal + Bayer)

Theolytics, a UK biotech harnessing viruses to combat cancer, today announced the closing of a US $6.8 million (UK £5 million) Series A round. The round was co-led by Epidarex Capital and Taiho Ventures LLC with participation from existing investor, Oxford Sciences Innovation (OSI). The financing will be used to progress the company's pipeline of candidates towards human clinical trials.

Theolytics is focused on creating a step-change in the oncolytic viral therapy field, by using its phenotypic screening platform to discover and develop highly efficacious, targeted candidates, suitable for intravenous delivery and optimised for a chosen cancer patient population.

Charlotte Casebourne, CEO of Theolytics said, "Oncolytic viruses represent a unique therapeutic paradigm within oncology. Theolytics' platform technology enables a fundamental shift in what is possible; combining the power of bioselection with a patient-centric approach to drug discovery, we are able to address many of the challenges that have prevented the field from delivering on its full potential. Our team are committed to discovering and developing candidates for some of the most challenging cancers, and I'm delighted that Epidarex and Taiho Ventures have chosen to support us on our journey."

Henning Steinhagen, Venture Partner at Epidarex Capital said, "The oncolytic viral therapy field continues to gain momentum and Theolytics caught our eye with their highly promising indication-specific bioselection platform. Theolytics combines multiple key features we are looking for when investing: world class science, highly driven innovators, and a disruptive technology that has the potential to generate a strong pipeline of proprietary and significantly more efficacious therapeutics. We look forward to supporting Theolytics in leveraging its innovative platform to establish a pipeline of patient-centric next-generation oncolytic viruses, which promises to dramatically improve the treatment of cancer."

Sakae Asanuma, President at Taiho Ventures, LLC, the corporate venture arm of Taiho Pharmaceutical Co. Ltd., said, "Taiho is delighted to co-lead this Series A financing and work with Theolytics to deliver the innovative oncolytic virotherapy generated by their unique proprietary platform technology, which should provide cancer patients with the promise of dramatically improving clinical outcomes."

Dr Kenneth Powell, Chair of the Board welcomed Henning Steinhagen, Venture Partner at Epidarex, and Sakae Asanuma, President at Taiho Ventures as new Board members, stating, "I look forward to working with our new investors to bring these promising approaches to cancer patients."

Media contacts:

Charlotte Casebourne, CEO

Scius Communications
Katja Stout

About Theolytics

Theolytics is focused on developing category changing cancer therapies in the form of oncolytic viruses. The company is pioneering a phenotypic screening approach to the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. Theolytics, which was founded in 2017 and is headquartered in Oxford, UK, is backed by Oxford Science Innovation (OSI) and international life sciences investors Epidarex Capital and Taiho Ventures, LLC.

About Epidarex Capital

Epidarex Capital is a transatlantic venture capital firm with a track record of building exceptional life science companies in emerging hubs in the US and UK. Epidarex's experienced team of early stage investors partner with entrepreneurs and leading research institutions to transform world-class science into highly innovative products addressing major unmet needs in the global healthcare market. For more information visit .

About Taiho Ventures, LLC

Taiho Ventures, LLC is the corporate venture arm of Taiho Pharmaceutical Co., Ltd., a Japanese specialty pharmaceutical company focusing on oncology, allergy and immunology, and urology. With $300M under management, we are actively investing in early-stage innovative companies strategically relevant to Taiho Pharmaceutical. We consider company creation, spinouts and the option-type of investments as well as pure equity investments.

Record changed: 2023-06-05


Picture [iito] [LSE] Business Portal 650x200px

More documents for Theolytics Ltd.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x300px

» top